Elise F. Villard
Sanofi R&D
Chilly, France
Chilly, France
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 16 publications
Regulation of HDL dysfunctionality by phosphatidylethanolamine links poly-unsaturated fatty acids with atherosclerotic cardiovascular diseases.
Journal: Molecular metabolism
Published: June 10, 2025
High Glucose Activates YAP Signaling to Promote Vascular Inflammation.
Journal: Frontiers in physiology
Published: February 09, 2021
Lipoprotein(a) Cellular Uptake Ex Vivo and Hepatic Capture In Vivo Is Insensitive to PCSK9 Inhibition With Alirocumab.
Journal: JACC. Basic to translational science
Published: December 26, 2019
PCSK9 inhibition with alirocumab reduces lipoprotein(a) levels in nonhuman primates by lowering apolipoprotein(a) production rate.
Journal: Clinical science (London, England : 1979)
Published: January 16, 2018
The complexity of lipoprotein (a) lowering by PCSK9 monoclonal antibodies.
Journal: Clinical science (London, England : 1979)
Published: October 18, 2016
PCSK9 Modulates the Secretion But Not the Cellular Uptake of Lipoprotein(a) Ex Vivo: An Effect Blunted by Alirocumab.
Journal: JACC. Basic to translational science
Published: October 01, 2016
Plasma cholesterol efflux capacity from human THP-1 macrophages is reduced in HIV-infected patients: impact of HAART.
Journal: Journal of lipid research
Published: January 10, 2015
Genetic determination of plasma cholesterol efflux capacity is gender-specific and independent of HDL-cholesterol levels.
Journal: Arteriosclerosis, thrombosis, and vascular biology
Published: February 02, 2013
Endogenous CETP activity as a predictor of cardiovascular risk: determination of the optimal range.
Journal: Atherosclerosis
Published: September 10, 2012
Elevated CETP activity improves plasma cholesterol efflux capacity from human macrophages in women.
Journal: Arteriosclerosis, thrombosis, and vascular biology
Published: August 21, 2012
Last Updated: 09/26/2026